Myeloperoxidase and coronary arterial disease: From research to clinical practice;Mieloperoxidase e doença arterial coronariana: Da pesquisa à prática clínica

Arquivos Brasileiros de Cardiologia

Volumn 91, Issue 1, 2008, Pages

  Roman, Raquel Melchior ^a,c,d   Wendland, Andrea Elisabet ^b,c   Polanczyk, Carisi Anne ^b,c  

^a Hospital Sao Vicente de Paulo   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d NONE   (Brazil)

Author keywords

Atherosclerosis; Coronary arteriosclerosis; Inflammation; Peroxidase

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MYELOPEROXIDASE; NITRIC OXIDE; BIOLOGICAL MARKER; PEROXIDASE;

ACUTE CORONARY SYNDROME; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CATALYSIS; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ENZYME BLOOD LEVEL; ENZYME MECHANISM; ENZYME METABOLISM; ENZYME POLYMORPHISM; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE REMODELING; HUMAN; INCIDENCE; LIPID OXIDATION; MUTATION; PREDICTOR VARIABLE; PROTEIN EXPRESSION; REVIEW; THORAX PAIN; ARTERIOSCLEROSIS; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; ENZYMOLOGY; LIPID METABOLISM; METABOLISM; PHYSIOLOGY; PROGNOSIS;

ACUTE CORONARY SYNDROME; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; HUMANS; LIPID METABOLISM; NITRIC OXIDE; PEROXIDASE; PROGNOSIS;

EID: 48249098289     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2008001300015     Document Type: Review

References (60)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340: 115-26.
2. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105: 1135-43.
3. Hansson GK. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med. 2005; 352: 1685-95.
4. Pearson TA, Mensah GA, Alexander RW, Anderson HL, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. Circulation. 2003; 107: 499-511.
5. Tsimikas S, Willerson JT, Ridker PM. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol. 2006; 47: 19-31.
6. Apple FS, Wu AHB, Mair J, Ravkilde J, Panteghini M, Tate H, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem. 2005; 51: 810-24.
7. Jaffe AS, Balbuin L, Apple FS. Biomarkers in acute cardiac disease. J Am Coll Cardiol. 2006; 48: 1-11.
8. Naghavi M, Libby P, Falk E, Casscells W, Litovsky JR, Badimon JJ, et al. From vulnerable plaque to vulnerable patient. Circulation. 2003; 108: 1664-78.
9. Hansson M, Olsson I, Nauseef WM. Biosynthesis, processing, and sorting of human myeloperoxidase. Arch Biochem Biophys. 2006; 445: 214-24.
10. Arnhold J. Free radicals - friends or froes? Properties, functions, and secretion of human myeloperoxidase. Biochemistry (Moscow). 2004; 69: 4-9.
11. Lau D, Baldus S. Myeloperoxidase and its contributory role in inflammatory vascular disease. Pharm Therap. 2006; 111: 16-26.
12. Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2005; 25: 1102-11.
13. Brennan ML, Hazen S. Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment. Curr Opin Lipidol. 2003, 14: 353-9.
14. Nicholls SJ, Hazen SL. The role of myeloperoxidase in the pathogenesis of coronary artery disease. Jpn J Infect Dis. 2004; 57: 21-2.
15. Podrez E, Abu-Soud HM, Hazen SL. Myeloperoxidase-generated oxidants and atherosclerosis. Free Radic Biol Med. 2000; 28 (12): 1717-25.
16. Zhang R, Brennan ML, Shen Z, MacPherson JC, Schmitt D, Molenda CE, et al. Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J Biol Chem. 2002; 277: 46116-22.
17. Heinecke JW. Mechanisms of oxidative damage by myeloperoxidase in atherosclerosis and other inflammatory disorders. J Lab Clin Med. 1999; 133: 321-5.
18. Podrez EA, Schmitt D, Hoff HF, Hazen SL. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest. 1999; 103: 1547-60.
19. Mohiuddin I, Chai H, Lin PH, Lumsden AB, Yao Q, Chen C. Nitrotyrosine and chlorotirosine: clinical significance and biological functions in the vascular system. J Surg Res. 2006; 133: 143-9.
20. Podrez EA, Febbraio M, Sheibani N, Schmitt D, Silversterin RL, Hajjar DP, et al. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Invest. 2000; 105: 1095-108.
21. Malle E, Marsche G, Panzenboeck U, Sattler W. Myeloperoxidase-mediated oxidation of high-density lipoproteins: fingerprints of newly recognized potential proatherogenic lipoproteins. Arch Biochem Biophys. 2006; 445: 245-55.
22. Nicholls S, Zheng L, Hazen SL. Formation of dysfunctional high-density lipoprotein by myeloperoxidase. Trends Cardiovasc Med. 2005; 15: 212-9.
23. Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest. 2004; 114: 529-41.
24. Abu-Soud HM, Hazen SL. Nitric oxide is a physiological substrate for mammalian peroxidases. J Biol Chem. 2000; 275: 37524-32.
25. Baldus S, Eiserich HP, Mani A, Castro L, Figueroa M, Chumley P, et al. Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. J Clin Invest. 2001; 108: 1759-70.
26. Vita JA, Brennan ML, Gokce N, Mann, S, Goormastic M, Shishehbor MH, Penn MS, et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation. 2004; 110: 1134-9.
27. Hazen SL. Myeloperoxidase and plaque vulnerability. Arterioscler Thromb Vasc Biol. 2004; 24: 1143-6.
28. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol. 2001; 158: 879-91.
29. Naruko T, Ueda M, Haze K, van der Wal A, van der Loos CM, Itoh A, et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation. 2002; 106: 2894-900.
30. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A. widespread coronary inflammation in unstable angina. N Engl J Med. 2002; 347: 5-12.
31. Fu X, Kassim SY, Parks WC, Heinecke JW. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7): a mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem. 2001; 276: 41279-87.
32. Sugiyama S, Kugiyama K, Aikawa M, Nakamura S, Ogawa H, Libby P. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vasc Biol. 2004; 24: 1309-14.
33. Baldus S, Heitzer T, Eiserich JP, Lau D, Mollnau H, Ortak M, et al. Myeloperoxidase enhances nitric oxide catabolism during myocardial ischemia and reperfusion. Free Radic Biol Med. 2004; 37: 902-11.
34. Askari AT, Brennan ML, Zhou X, Drinko J, Morehead A, Thomas JD, et al. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med. 2003; 197: 615-24.
35. Vasilyev N, Williams T, Brennan ML, Unzek S, Zhou X, Heinecke JW, et al. Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction. Circulation. 2005; 112: 2812-20.
36. Kutter D, Devaquet P, Vanderstocken G, Paulus JM, Marchal V, Gothot A. Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit? Acta Haematol. 2000; 104: 10-5.
37. Chevrier I, Tregouet DA, Massounet-Castel S, Beaune P, Loriot MA. Myeloperoxidase genetic polymorphisms modulate human neutrophil enzyme activity: genetic determinants for atherosclerosis. Atherosclerosis. 2006; 188: 150-4.
38. Nikpoor B, Turecki G, Fournier C, Théroux P, Rouleau GA. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J. 2001; 142: 336-9.
39. Asselbergs FW, Reynolds WF, Cohen-Tervaert JW. Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease. Am J Med. 2004; 116: 429-30.
40. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 2001; 286: 2136-42.
41. Melchior R, Camargo PVS, Rohde LE, Lucchesse A, Campagnolo N, Alberton DL, et al. Unbalanced predictive value of C- reactive protein and myeloperoxidase in stable angina patients. [Abstract]. Circulation. 2005; 112 (17): 626.
42. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003; 349: 1595-604.
43. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Münzel T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003; 108: 1440-5.
44. Roman RM. Valor prognóstico da mieloperoxidase na doença arterial coronariana: comparação entre pacientes estáveis e instáveis [dissertação de mestrado]. Porto Alegre: Universidade Federal do Rio Grande do Sul, 2006.
45. Cavusoglu E, Ruwende C, Eng C, Chopra V, Wanamadala S, Clark LT, et al. Usefulness of baseline plasma myeloperoxidase levels as independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. Am J Cardiol. 2007; 99: 1364-8.
46. Biasucci LM, D'Onofrio G, Liuzzo G, Zini G, Monaco C, Caligiuri G, et al. Intracellular neutrophil myeloperoxidase is reduced in unstable angina and acute myocardial infarction, but its reduction is not related to ischemia. J Am Coll Cardiol. 1996; 27: 611-6.
47. Gach O, Biemar C, Nys M, Deby-Dupont G, Chapelle JP, Deby C, et al. Early release of neutrophil markers of activation after direct stentig in patients with unstable angina. Coron Artery Dis. 2005; 16: 59-65.
48. Khan SQ, Keely D, Quinn P, Davies JE, Ng LL. Myeloperoxidase aids prognostication together with N-terminal pro-B-Type natriuretic peptide in high-risk patients with acute ST elevation myocardial infarction. Heart. 2007; 93: 826-31.
49. Mocatta TJ, Pilbrow AP, Cameron VA, Senthilmohan R, Frampton CM, Richards AM, et al. Plasma concentrations of myeloperoxidase predict mortality after myocardial infartcion. J Am Coll Cardiol. 2007; 49: 1993-2000.
50. Tang W, Brennan ML, Philip K, Tong W, Mann S, Van Lente F, et al. Plasma myeloperoxidase levels in patients with chronic heart failure. Am J Cardiol. 2006; 98: 796-9.
51. Ng LL, Pathik B, Loke IW, Squire IB, Davies JE. Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. Am Heart J. 2006; 152: 94-101.
52. Meuwese MC, Stroes WS, Hazen SL, Miert JN, Kuivenhoven JA, Schub RG, et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals. J Am Coll Cardiol. 2007; 50: 159-65.
53. Shishehbor MH, Aviles RJ, Brennan ML, Fu X, Goormastic M, Pearce GL, et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA. 2003; 289: 1675-80.
54. Shishehbor MH, Brennan ML, Aviles RJ, Fu X, Penn MS, Sprecher DL, et al. Statin promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation. 2003; 108: 426-31.
55. Zhou T, Zhou S, Qi S, Shen X, Zeng G, Zhou H. The effect of atorvastatin on serum myeloperoxidase and CRP levels in patients with acute coronary syndrome. Clin Chim Acta. 2006; 368: 168-72.
56. Baldus S, Rudolph V, Roiss M, Ito WD, Rudolph TK, Eiserich JP, et al. Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation. 2006; 113: 1871-8.
57. Roberts CK, Won D, Pruthi S, Kurtovic S, Sindhu RK, Vaziri ND, et al. Effect of a short-term diet and exercise intervention on oxidative stress, inflammation, MMP-9, and monocyte chemotactic activity in men with metabolic syndrome factors. J Appl Physiol. 2006; 100: 1657-65.
58. Jaffe AS, Katus H. Acute coronary syndrome biomarkers: the need for more adequate reporting. Circulation. 2004; 110: 104-6.
59. Leckie MJ, Gomma AH, Purcell IF, Nyawo B, Dewar A, Okrongly D, et al. Automated quantitation of peripheral blood neutrophil activation in patients with myocardial ischaemia. Int J Cardiol. 2004; 95: 307-13.
60. Chang PY, Wu TL, Hung CC, Tsao KC, Sun CF, Wu LL, et al. Development of an ELISA for myeloperoxidase on microplate: normal reference values and effect of temperature on specimen preparation. Clin Chim Acta. 2006; 373: 158-63.